Kathleen Gallagher Weber Net Worth

The estimated Net Worth of Kathleen Gallagher Weber is at least $2.51 Milhão dollars as of 19 December 2023. Ms Weber owns over 24,129 units of Orasure Technologies stock worth over $1,082,475 and over the last 6 years she sold OSUR stock worth over $311,838. In addition, she makes $1,119,360 as Exec. VP & Bus. Unit Leader of Molecular Solutions at Orasure Technologies.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms Weber OSUR stock SEC Form 4 insiders trading

Ms has made over 2 trades of the Orasure Technologies stock since 2020, according to the Form 4 filled with the SEC. Most recently she sold 24,129 units of OSUR stock worth $194,238 on 19 December 2023.

The largest trade she's ever made was selling 24,129 units of Orasure Technologies stock on 19 December 2023 worth over $194,238. On average, Ms trades about 2,625 units every 84 days since 2019. As of 19 December 2023 she still owns at least 254,700 units of Orasure Technologies stock.

You can see the complete history of Ms Weber stock trades at the bottom of the page.

Ms. Kathleen Gallagher Weber biography

Kathleen Gallagher Weber is the Exec. VP & Bus. Unit Leader of Molecular Solutions at Orasure Technologies.

What is the salary of Ms Weber?

As the Exec. VP & Bus. Unit Leader of Molecular Solutions of Orasure Technologies, the total compensation of Ms Weber at Orasure Technologies is $1,119,360. There are 3 executives at Orasure Technologies getting paid more, with Stephen Tang having the highest compensation of $2,114,820.

How old is Ms Weber?

Ms Weber is 54, she's been the Exec. VP & Bus. Unit Leader of Molecular Solutions of Orasure Technologies since . There are 8 older and 9 younger executives at Orasure Technologies. The oldest executive at Orasure Technologies Inc. is Ronny Lancaster, 68, who is the Independent Director.

What's Ms Weber's mailing address?

Kathleen's mailing address filed with the SEC is C/O ORASURE TECHNOLOGIES, INC., 220 EAST FIRST STREET, BETHLEHEM, PA, 18015.

Insiders trading at Orasure Technologies

Over the last 21 years, insiders at Orasure Technologies have traded over $21,897,384 worth of Orasure Technologies stock and bought 196,200 units worth $1,037,188 . The most active insiders traders include Douglas A Michels, Ronald H Spair, eMichael J Gausling. On average, Orasure Technologies executives and independent directors trade stock every 43 days with the average trade being worth of $221,123. The most recent stock trade was executed by Kathleen Gallagher Weber on 19 December 2023, trading 24,129 units of OSUR stock currently worth $194,238.

What does Orasure Technologies do?

based in bethlehem, pennsylvania, orasure technologies is a leader in the development, manufacture and distribution of oral fluid diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. these products include tests for the detection of antibodies to the hiv virus, including the oraquick® in-home hiv test, oraquick advance® rapid hiv-1/2 antibody test and the orasure® hiv-1 oral specimen collection device, a test for antibodies to the hcv virus, the oraquick® hcv rapid antibody test, and oral fluid testing solutions for drugs of abuse testing, including intercept® oral fluid drug testing system and q.e.d.® saliva alcohol test. orasure also manufactures and sells several leading cryosurgical products. these include: histofreezer®, a product for the cryosurgical removal of common and plantar warts and several other benign skin lesions, sold to the professional or physician office market, as well as an over-the-counter product fo

Complete history of Ms Weber stock trades at Orasure Technologies

Orasure Technologies executives and stock owners

Orasure Technologies executives and other stock owners filed with the SEC include:

• Stephen Tang,
  President, Chief Executive Officer, Director
• Dr. Stephen S. Tang,
  Pres, CEO & Director
• Roberto Cuca,
  Chief Financial Officer
• Kathleen Gallagher Weber,
  Exec. VP & Bus. Unit Leader of Molecular Solutions
• Jack Jerrett,
  Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
• Kathleen Weber,
  Executive Vice President, Business Unit Leader, Molecular Solutions at DNAG
• Scott Gleason,
  Sr. VP of Investor Relations & Corp. Communications and Interim CFO
• Michael Celano,
  Independent Chairman of the Board
• Ronny Lancaster,
  Independent Director
• Eamonn Hobbs,
  Independent Director
• Mara Aspinall,
  Independent Director
• James Datin,
  Independent Director
• David Shulkin,
  Independent Director
• Lelio Marmora,
  Director
• Michele Miller,
  Vice President - Finance, Controller, Assistant Secretary
• Lisa Nibauer,
  Executive Vice President, Business Unit Leader, Infectious Disease
• Amy Steigerwalt,
  VP of HR
• David A. Rappaport C.F.A., CFA,
  Sr. VP Corp. Devel., Strategy & Integration
• Carrie Eglinton Manner,
  Pres, CEO & Director
• Michele Marie Miller,
  VP of Fin., Controller & Assistant Sec.
• Agnieszka M. Gallagher J.D.,
  Gen. Counsel, Chief Compliance Officer & Sec.
• Lisa Nibauer,
  Pres of Diagnostics
• Jeanne Mell,
  VP of Corp. Communications
• Michele Marie Anthony,
  SVP Finance & CAO
• Douglas G Watson,
  Director
• Mark L Kuna,
  VP & Controller
• Roger L Pringle,
  Director
• Michael Reed,
  SVP R&D and CSO
• Ronald H Spair,
  Exec. VP & CFO
• Douglas A Michels,
  President and CEO
• Brian Smith,
  EVP & BU Lead - Molecular
• Nancy J Gagliano,
  Director
• Gregory B Lawless,
  Director
• Aradhana Sarin,
  Director
• Gerald M Ostrov,
  Director
• Eric Whitters,
  SVP, Research and Development
• Stephen R Lee,
  EVP & Chief Science Officer
• P Michael Formica,
  Exec. VP - Operations
• Michael J Gausling,
  President & CEO
• Joseph E Zack,
  Exec. VP, Marketing & Sales
• Manuel O. Mendez,
  VP, Marketing and Sales
• Frank G Hausmann,
  Director
• Jack Goldstein,
  Director
• Carter H Eckert,
  Director
• Ii Anthony Zezzo,
  EVP & BU Lead - Infectious
• Charles W Patrick,
  Director
• John P. Kenny,
  Director
• Robert W. Mc Mahon,
  Director
• Agnieszka Gallagher,
  General Counsel & CCO
• Scott Gleason,
  Interim CFO/SVP IR
• Anne Clem Whitaker,
  Director
• Manner Carrie Eglinton,
  President & CEO
• Kenneth J Mc Grath,
  Chief Financial Officer